| Dr Hassan Zulfiqar, MD | |
|
1690 Dunlawton Ave, Suite # 210, Port Orange, FL 32127-8980 | |
| (386) 763-4920 | |
| (386) 763-4939 |
| Full Name | Dr Hassan Zulfiqar |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 34 Years |
| Location | 1690 Dunlawton Ave, Port Orange, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487684171 | NPI | - | NPPES |
| 46913 | Other | FL | BCBS |
| 262929100 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | ME78417 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Halifax Health Medical Center | Daytona beach, FL | Hospital |
| Halifax Health /uf Health Medical Center Of Delton | Deltona, FL | Hospital |
| Adventhealth Daytona Beach | Daytona beach, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Halifax Healthcare Systems Inc | 1254238090 | 278 |
| Advanced Gastroenterology Health Care Centers | 9830084508 | 9 |
News Archive
Brian Samuels, M.D., Ph.D., assistant professor in the University of Alabama at Birmingham Department of Ophthalmology, has received a five-year, $1.5 million grant from the National Eye Institute to explore the links between circadian fluctuations and glaucoma. This is Samuels' first R01 grant.
More than a third of women who suffer from diabetes during pregnancy develop type 2 diabetes within five years and those most at risk can be predicted from their blood glucose levels at diagnosis, according to a study published in the June issue of the Postgraduate Medical Journal .
Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare professionals about the safe and appropriate use of its products.
Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced fiscal second quarter results for the period ended July 31, 2009.
› Verified 8 days ago
| Entity Name | Halifax Healthcare Systems Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245283530 PECOS PAC ID: 1254238090 Enrollment ID: O20031218000443 |
News Archive
Brian Samuels, M.D., Ph.D., assistant professor in the University of Alabama at Birmingham Department of Ophthalmology, has received a five-year, $1.5 million grant from the National Eye Institute to explore the links between circadian fluctuations and glaucoma. This is Samuels' first R01 grant.
More than a third of women who suffer from diabetes during pregnancy develop type 2 diabetes within five years and those most at risk can be predicted from their blood glucose levels at diagnosis, according to a study published in the June issue of the Postgraduate Medical Journal .
Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare professionals about the safe and appropriate use of its products.
Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced fiscal second quarter results for the period ended July 31, 2009.
› Verified 8 days ago
| Entity Name | Advanced Gastroenterology Health Care Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790790277 PECOS PAC ID: 9830084508 Enrollment ID: O20040220000397 |
News Archive
Brian Samuels, M.D., Ph.D., assistant professor in the University of Alabama at Birmingham Department of Ophthalmology, has received a five-year, $1.5 million grant from the National Eye Institute to explore the links between circadian fluctuations and glaucoma. This is Samuels' first R01 grant.
More than a third of women who suffer from diabetes during pregnancy develop type 2 diabetes within five years and those most at risk can be predicted from their blood glucose levels at diagnosis, according to a study published in the June issue of the Postgraduate Medical Journal .
Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare professionals about the safe and appropriate use of its products.
Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced fiscal second quarter results for the period ended July 31, 2009.
› Verified 8 days ago
| Entity Name | Imacs, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669779906 PECOS PAC ID: 1153599121 Enrollment ID: O20110718000441 |
News Archive
Brian Samuels, M.D., Ph.D., assistant professor in the University of Alabama at Birmingham Department of Ophthalmology, has received a five-year, $1.5 million grant from the National Eye Institute to explore the links between circadian fluctuations and glaucoma. This is Samuels' first R01 grant.
More than a third of women who suffer from diabetes during pregnancy develop type 2 diabetes within five years and those most at risk can be predicted from their blood glucose levels at diagnosis, according to a study published in the June issue of the Postgraduate Medical Journal .
Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare professionals about the safe and appropriate use of its products.
Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced fiscal second quarter results for the period ended July 31, 2009.
› Verified 8 days ago
| Entity Name | Town Center Medical Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427498724 PECOS PAC ID: 1759517568 Enrollment ID: O20131127001400 |
News Archive
Brian Samuels, M.D., Ph.D., assistant professor in the University of Alabama at Birmingham Department of Ophthalmology, has received a five-year, $1.5 million grant from the National Eye Institute to explore the links between circadian fluctuations and glaucoma. This is Samuels' first R01 grant.
More than a third of women who suffer from diabetes during pregnancy develop type 2 diabetes within five years and those most at risk can be predicted from their blood glucose levels at diagnosis, according to a study published in the June issue of the Postgraduate Medical Journal .
Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare professionals about the safe and appropriate use of its products.
Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced fiscal second quarter results for the period ended July 31, 2009.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hassan Zulfiqar, MD 1690 Dunlawton Ave, Suite # 210, Port Orange, FL 32127-8980 Ph: (386) 763-4920 | Dr Hassan Zulfiqar, MD 1690 Dunlawton Ave, Suite # 210, Port Orange, FL 32127-8980 Ph: (386) 763-4920 |
News Archive
Brian Samuels, M.D., Ph.D., assistant professor in the University of Alabama at Birmingham Department of Ophthalmology, has received a five-year, $1.5 million grant from the National Eye Institute to explore the links between circadian fluctuations and glaucoma. This is Samuels' first R01 grant.
More than a third of women who suffer from diabetes during pregnancy develop type 2 diabetes within five years and those most at risk can be predicted from their blood glucose levels at diagnosis, according to a study published in the June issue of the Postgraduate Medical Journal .
Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare professionals about the safe and appropriate use of its products.
Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced fiscal second quarter results for the period ended July 31, 2009.
› Verified 8 days ago
Vrushak Deshpande, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3635 Clyde Morris Blvd Ste 100, Port Orange, FL 32129 Phone: 386-788-1242 Fax: 386-756-8802 | |
Dr. Gregory J. Stella, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 3635 S Clyde Morris Blvd, Ste 100, Port Orange, FL 32129 Phone: 386-788-1242 Fax: 386-788-4255 | |
Souheil Moussly, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3890 Turtle Creek Dr, Port Orange, FL 32129 Phone: 386-756-4400 Fax: 386-756-3031 | |
Robert Morris Harpold, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3953 S Nova Rd Ste B, Port Orange, FL 32127 Phone: 386-788-4911 Fax: 844-388-6186 | |
Dr. Ashraf S Elsakr, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 840 Dunlawton Ave, Ste A, Port Orange, FL 32127 Phone: 386-304-9672 Fax: 386-304-9673 | |
Nikenston Moise, PA Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 3890 Turtle Creek Dr Ste C, Port Orange, FL 32127 Phone: 386-756-4400 | |
Raxitkumar Jinjuvadia, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3635 Clyde Morris Blvd Ste 100, Port Orange, FL 32129 Phone: 386-788-1242 Fax: 386-756-8802 |